Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2015 2
2016 2
2017 1
2018 1
2019 3
2020 3
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial.
Jongsma MME, Aardoom MA, Cozijnsen MA, van Pieterson M, de Meij T, Groeneweg M, Norbruis OF, Wolters VM, van Wering HM, Hojsak I, Kolho KL, Hummel T, Stapelbroek J, van der Feen C, van Rheenen PF, van Wijk MP, Teklenburg-Roord STA, Schreurs MWJ, Rizopoulos D, Doukas M, Escher JC, Samsom JN, de Ridder L. Jongsma MME, et al. Among authors: cozijnsen ma. Gut. 2022 Jan;71(1):34-42. doi: 10.1136/gutjnl-2020-322339. Epub 2020 Dec 31. Gut. 2022. PMID: 33384335 Free PMC article. Clinical Trial.
Reply.
Cozijnsen MA, Turner D. Cozijnsen MA, et al. Clin Gastroenterol Hepatol. 2020 Feb;18(2):525-526. doi: 10.1016/j.cgh.2019.06.021. Epub 2019 Jun 20. Clin Gastroenterol Hepatol. 2020. PMID: 31228571 No abstract available.
Serum Immune Profiling in Paediatric Crohn's Disease Demonstrates Stronger Immune Modulation With First-Line Infliximab Than Conventional Therapy and Pre-Treatment Profiles Predict Clinical Response to Both Treatments.
Jongsma MME, Costes LMM, Tindemans I, Cozijnsen MA, Raatgreep RHC, van Pieterson M, Li Y, Escher JC, de Ridder L, Samsom JN. Jongsma MME, et al. Among authors: cozijnsen ma. J Crohns Colitis. 2023 Aug 21;17(8):1262-1277. doi: 10.1093/ecco-jcc/jjad049. J Crohns Colitis. 2023. PMID: 36934327 Free PMC article. Clinical Trial.
Prophylactic drug management for febrile seizures in children.
Offringa M, Newton R, Cozijnsen MA, Nevitt SJ. Offringa M, et al. Among authors: cozijnsen ma. Cochrane Database Syst Rev. 2017 Feb 22;2(2):CD003031. doi: 10.1002/14651858.CD003031.pub3. Cochrane Database Syst Rev. 2017. PMID: 28225210 Free PMC article. Updated. Review.
Evaluation of exclusive enteral nutrition and corticosteroid induction treatment in new-onset moderate-to-severe luminal paediatric Crohn's disease.
Jongsma MME, Vuijk SA, Cozijnsen MA, van Pieterson M, Norbruis OF, Groeneweg M, Wolters VM, van Wering HM, Hojsak I, Kolho KL, van Wijk MP, Teklenburg-Roord STA, de Meij TGJ, Escher JC, de Ridder L. Jongsma MME, et al. Among authors: cozijnsen ma. Eur J Pediatr. 2022 Aug;181(8):3055-3065. doi: 10.1007/s00431-022-04496-7. Epub 2022 Jun 8. Eur J Pediatr. 2022. PMID: 35672586 Free PMC article.
Development and Validation of the Mucosal Inflammation Noninvasive Index For Pediatric Crohn's Disease.
Cozijnsen MA, Ben Shoham A, Kang B, Choe BH, Choe YH, Jongsma MME, Russell RK, Ruemmele FM, Escher JC, de Ridder L, Koletzko S, Martín-de-Carpi J, Hyams J, Walters T, Griffiths A, Turner D. Cozijnsen MA, et al. Clin Gastroenterol Hepatol. 2020 Jan;18(1):133-140.e1. doi: 10.1016/j.cgh.2019.04.012. Epub 2019 Apr 10. Clin Gastroenterol Hepatol. 2020. PMID: 30981008
13 results